Weight (kg) or BMIc
|
SHAPE-2 [18], 2015, 16 weeks
| | | | |
Exercise + diet (Ex+WL)
|
80.4
|
74.9
|
−5.5
|
−5.58 (−6.32 to −4.84)
|
Ex+WL vs WL
|
Reduced calorie diet (WL)
|
80.3
|
75.4
|
−4.9
|
− 4.95 (−5.69 to −4.21)
|
−0.63 (−1.23 to −0.04)
|
Control
|
80.4
|
80.4
|
0.1
|
Referent
| |
NEW trial [17], 2012, 12 months
| | | | |
Exercise + diet
|
82.5
|
72.7
|
−9.8
|
P < 0.001
|
Ex+WL vs WL, P = 0.1
|
Exercise
|
83.7
|
80.9
|
−2.8
|
P = 0.02
|
Ex+WL vs Ex, P < 0.001
|
Reduced calorie diet
|
84.0
|
74.9
|
−9.1
|
P < 0.001
|
Ex vs WL, P < 0.001
|
Control
|
84.2
|
83.7
|
−0.5
|
Referent
| |
ALPHA trial [24], 2010, 12 months
| | | | |
Exercise
| | |
−2.3
|
−1.80 (−2.60 to −1.00)
| |
Control
| | |
−0.5
|
Referent
| |
SHAPE-1 [3], 2009, 12 months
| | | | | |
Exercise
|
73.6
|
72.2
|
−1.4
|
N/A
| |
Control
|
74.8
|
74.0
|
−0.8
| | |
Orsatti et al. [25], 2008, BMI, 16 weeks
| | | | |
Exercise
|
28.8c
|
29.6c
|
0.6c
|
P = 0.57
| |
Control
|
27.6c
|
27.1c
|
−0.5c
|
Referent
| |
PATH trial [22, 23], 2004, 12 months
| | | | |
Exercise
|
81.6
|
80.3
|
−1.6
|
P = 0.1
| |
Control
|
81.7
|
81.8
|
0.1
|
Referent
| |
Total estradiol (pg/ml)
|
SHAPE-2 [18], 2015
| | | | |
Exercise + diet
|
3.69
|
3.22
|
−12.7
|
0.83 (0.73–0.95)
|
Ex+WL vs WL
|
Reduced calorie diet
|
4.20
|
3.62
|
−13.8
|
0.86 (0.75–0.98)
|
0.97 (0.87–1.08)
|
Control
|
3.89
|
4.01
|
3.11
|
Referent
| |
NEW trial [17], 2012
| | | | |
Exercise + diet
|
11.5
|
9.2
|
−20.3
|
P < 0.001
|
Ex+WL vs WL, P = 0.07
|
Exercise
|
11.5
|
11.0
|
−4.9
|
P = 0.1
|
Ex+WL vs Ex, P < 0.001
|
Reduced calorie diet
|
11.6
|
9.7
|
−16.2
|
P < 0.001
|
Ex vs WL, P = 0.002
|
Control
|
10.9
|
11.4
|
4.9
|
Referent
| |
ALPHA trial [24], 2010
| | | | |
Exercise
|
10.1
|
8.7
| |
0.93 (0.88–0.98)
| |
Control
|
10.2
|
9.9
| |
Referent
| |
SHAPE-1 [3], 2009
| | | | |
Exercise
|
8.8
|
8.1
|
−7.3
|
0.99 (0.95–1.02)
| |
Control
|
9.8
|
8.8
|
−10.2
|
Referent
| |
Orsatti et al. [25], 2008
| | | | |
Exercise
|
21.5
|
23.2
| |
P = 0.56
| |
Control
|
25.1
|
27.4
| |
Referent
| |
PATH trial [22, 23], 2004
| | | | |
Exercise
|
18.3
|
17.5
|
−4.4
|
P = 0.32
| |
Control
|
17.9
|
17.8
|
−0.6
|
Referent
| |
Estrone (pg/ml)
|
SHAPE-2 [18], 2015
| | | | |
Exercise + diet
|
19.9
|
18.5
|
−6.67
|
0.92 (0.82:1.02)
|
Ex+WL vs WL
|
Reduced calorie diet
|
20.4
|
20.1
|
−1.26
|
0.98 (0.88:1.08)
|
0.94 (0.86:1.02)
|
Control
|
20.1
|
20.4
|
3.11
|
Referent
| |
NEW trial [17], 2012
| | | | |
Exercise + diet
|
33.9
|
30.2
|
−11.1
|
P < 0.001
|
Ex+WL vs WL, P = 0.17
|
Exercise
|
34.8
|
32.9
|
−5.5
|
P < 0.01
|
Ex+WL vs Ex, P = 0.1
|
Reduced calorie diet
|
35.2
|
31.8
|
−9.6
|
P < 0.001
|
Ex vs WL, P = 0.3
|
Control
|
32.0
|
34.6
|
8.1
|
Referent
| |
ALPHA trial [24], 2010
|
31.4
|
29.4
| | | |
Exercise
|
31.3
|
30.6
| |
0.99 (0.94–1.03)
| |
Control
| | | |
Referent
| |
SHAPE-1 [3], 2009
| | | | |
Exercise
|
30.6
|
27.6
|
−9.7
|
0.97 (0.92–1.04)
| |
Control
|
28.0
|
27.3
|
−3.4
|
Referent
| |
PATH trial [22, 23], 2004
| | | | |
Exercise
|
44.2
|
42.5
|
−1.8
|
P = 0.13
| |
Control
|
43.9
|
45.4
|
3.9
|
Referent
| |
Free estradiol (pg/ml)
|
SHAPE-2 [18], 2015
| | | | |
Exercise + diet
|
0.09
|
0.07
|
−19.1
|
0.77 (0.67–0.88)
|
Ex+WL vs WL
|
Reduced calorie diet
|
0.10
|
0.08
|
−17.7
|
0.80 (0.70–0.92)
|
0.96 (0.85–1.02)
|
Control
|
0.09
|
0.10
|
3.23
|
Referent
| |
NEW trial [17], 2012
| | | | |
Exercise + diet
|
0.32
|
0.23
|
−26
|
P < 0.001
|
Ex+WL vs WL, P = 0.06
|
Exercise
|
0.30
|
0.29
|
−4.7
|
P = 0.08
|
Ex+WL vs Ex, P < 0.001
|
Reduced calorie diet
|
0.31
|
0.24
|
−21.4
|
P < 0.001
|
Ex vs WL, P < 0 .001
|
Control
|
0.30
|
0.33
|
6.3
|
Referent
| |
ALPHA trial [24], 2010
| | | | |
Exercise
|
0.24
|
0.21
| |
0.91 (0.87–0.96)
| |
Control
|
0.25
|
0.24
| |
Referent
| |
SHAPE-1 [3], 2009
| | | | |
Exercise
|
0.22
|
0.21
|
−7.3
|
1.00 (0.96–1.04)
| |
Control
|
0.25
|
0.23
|
−10.2
|
Referent
| |
PATH trial [22, 23], 2004
| | | | |
Exercise
|
0.49
|
0.46
|
−6.2
|
P = 0.2
| |
Control
|
0.47
|
0.47
|
0.0
|
Referent
| |
Testosterone (pg/ml)
|
SHAPE-2 [18], 2015
| | | | |
Exercise + diet
|
186
|
172
|
−7.63
|
0.96 (0.87–1.05)
|
Ex+WL vs WL
|
Reduced calorie diet
|
197
|
189
|
−3.76
|
1.01 (0.92–1.10)
|
0.95 (0.88–1.02))
|
Control
|
194
|
186
|
4.07
|
Referent
| |
NEW trial [17], 2012
| | | | |
Exercise + diet
|
239
|
225
|
−5.9
|
P = 0.02
|
Ex+WL vs WL, P = 0.07
|
Exercise
|
248
|
236
|
−4.9
|
P = 0.24
|
Ex+WL vs Ex, P = 0.24
|
Reduced calorie diet
|
239
|
236
|
−0.9
|
P = 0.4
|
Ex vs WL, P = 0.67
|
Control
|
228
|
232
|
1.8
|
Referent
| |
ALPHA trial [24], 2010
| | | | |
Exercise
|
239
|
234
| |
0.99 (0.95–1.03)
| |
Control
|
231
|
237
| |
Referent
| |
SHAPE-1 [3], 2009
| | | | |
Exercise
|
528
|
507
|
−4.0
|
0.98 (0.94–1.01)
| |
Control
|
535
|
526
|
−1.6
|
Referent
| |
PATH trial [22, 23], 2004
| | | | |
Exercise
|
211
|
208
| |
P = 0.94
| |
Control
|
223
|
218
| |
Referent
| |
Androstenedione (pg/ml)
|
SHAPE-2 [18], 2015
| | | | |
Exercise + diet
|
573
|
488
|
−14.7
|
0.87 (0.76–1.00)
|
Ex+WL vs WL
|
Reduced calorie diet
|
562
|
537
|
−4.5
|
0.97 (0.85–1.12)
|
0.90 (0.80–1.01)
|
Control
|
575
|
560
|
−2.6
|
Referent
| |
NEW trial [17], 2012
| | | | |
Exercise + diet
|
526
|
508
|
−3.5
|
P = 0.22
|
Ex+WL vs WL, P = 0.26
|
Exercise
|
502
|
496
|
−1.2
|
P = 0.75
|
Ex+WL vs Ex, P = 0.25
|
Reduced calorie diet
|
511
|
518
|
1.4
|
P = 0.83
|
Ex vs WL, P = 0.93
|
Control
|
487
|
494
|
1.5
|
Referent
| |
ALPHA trial [24], 2010
| | | | |
Exercise
|
578
|
572
| |
0.98 (0.93–1.03)
| |
Control
|
553
|
577
| |
Referent
| |
SHAPE-1 [3], 2009
| | | | |
Exercise
|
1146
|
1115
|
−2.7
|
0.97 (0.93–1.01)
| |
Control
|
1172
|
1199
|
2.3
|
Referent
| |
PATH trial [22, 23], 2004
| | | | |
Exercise
|
533
|
480
| |
P = 0.89
| |
Control
|
585
|
525
| |
Referent
| |
Free testosterone (pg/ml)
|
SHAPE-2 [18], 2015
| | | | |
Exercise + diet
|
2.44
|
2.01
|
−17.7
|
0.84 (0.76–0.93)
|
Ex+WL vs WL
|
Reduced calorie diet
|
2.53
|
2.25
|
−11.2
|
0.91 (0.83–1.01)
|
0.92 (0.85–0.99)
|
Control
|
2.71
|
2.61
|
−3.9
|
Referent
| |
NEW trial [17], 2012
| | | | |
Exercise + diet
|
5.3
|
4.5
|
−15.6
|
P < 0.001
|
Ex+WL vs WL, P = 0.02
|
Exercise
|
5.1
|
4.9
|
−4.5
|
P = 0.2
|
Ex+WL vs Ex, P < 0.001
|
Reduced calorie diet
|
5.1
|
4.6
|
−10.0
|
P < 0.001
|
Ex vs WL, P = 0.02
|
Control
|
4.9
|
5.1
|
2.6
|
Referent
| |
ALPHA trial [24], 2010
| | | | |
Exercise
|
3.5
|
3.3
| |
0.96 (0.92–1.01)
| |
Control
|
3.5
|
3.5
| |
Referent
| |
SHAPE-1 [3], 2009
| | | | |
Exercise
|
8.7
|
8.5
|
−2.9
|
0.99 (0.95–1.03)
| |
Control
|
8.7
|
8.5
|
−1.8
|
Referent
| |
PATH trial [22, 23], 2004
| | | | |
Exercise
|
4.6
|
4.3
| |
P = 0.42
| |
Control
|
4.7
|
4.6
| |
Referent
| |
SHBG (nmol/l)
|
SHAPE-2 [18], 2015
| | | | |
Exercise + diet
|
49.3
|
58.6
|
19.0
|
1.21 (1.12–1.30)
|
Ex+WL vs WL
|
Reduced calorie diet
|
50.7
|
57.1
|
12.6
|
1.14 (1.07–1.23)
|
1.05 (1.00–1.12)
|
Control
|
44.2
|
44.0
|
−0.30
|
Referent
| |
NEW trial [17], 2012
| | | | |
Exercise + diet
|
34.1
|
42.9
|
25.8
|
P < 0.001
|
Ex+WL vs WL, P = 0.41
|
Exercise
|
39.1
|
38.8
|
0.7
|
P = 0.41
|
Ex+WL, vs Ex P < 0.001
|
Reduced calorie diet
|
35.8
|
43.8
|
22.4
|
P < 0.001
|
Ex vs WL, P < 0.001
|
Control
|
34.7
|
33.7
|
−2.7
|
Referent
| |
ALPHA trial [24], 2010
| | | | |
Exercise
|
40.3
|
41.9
| |
1.04 (1.02–1.07)
| |
Control
|
38.1
|
38.4
| |
Referent
| |
SHAPE-1 [3], 2009
| | | | |
Exercise
|
33.9
|
33.6
|
−0.7
|
0.98 (0.92–1.04)
| |
Control
|
34.7
|
33.6
|
−3.3
|
Referent
| |
PATH trial [22, 23], 2004
| | | | |
Exercise
|
35.2
|
38.3
|
8.8
|
P = 0.10
| |
Control
|
35.8
|
36.7
|
2.5
|
Referent
| |